menu
    • menu
    [{"orgOrder":0,"company":"Gedeon Richter","sponsor":"Mycenax Biotech","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase I","graph3":"Gedeon Richter","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.02,"dosageForm":"Injection","sponsorNew":"Gedeon Richter \/ Gedeon Richter","highestDevelopmentStatusID":"6","companyTruncated":"Gedeon Richter \/ Gedeon Richter"},{"orgOrder":0,"company":"Gedeon Richter","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"HUNGARY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Relugolix","moa":"||Gonadotropin-releasing hormone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Gedeon Richter","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Gedeon Richter \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gedeon Richter \/ Inapplicable"},{"orgOrder":0,"company":"Gedeon Richter","sponsor":"Myovant Sciences","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Relugolix","moa":"||Gonadotropin-releasing hormone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Gedeon Richter","amount2":0.080000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.080000000000000002,"dosageForm":"Tablet","sponsorNew":"Gedeon Richter \/ Gedeon Richter","highestDevelopmentStatusID":"15","companyTruncated":"Gedeon Richter \/ Gedeon Richter"},{"orgOrder":0,"company":"Gedeon Richter","sponsor":"Sumitomo","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"HUNGARY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Relugolix","moa":"||Gonadotropin-releasing hormone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Gedeon Richter","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Gedeon Richter \/ Sumitomo","highestDevelopmentStatusID":"15","companyTruncated":"Gedeon Richter \/ Sumitomo"},{"orgOrder":0,"company":"Gedeon Richter","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"HUNGARY","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"RGH-706","moa":"TAAR1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Gedeon Richter","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Gedeon Richter \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Gedeon Richter \/ Inapplicable"},{"orgOrder":0,"company":"Gedeon Richter","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"HUNGARY","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase I","graph3":"Gedeon Richter","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Gedeon Richter \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gedeon Richter \/ Inapplicable"},{"orgOrder":0,"company":"Gedeon Richter","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"HUNGARY","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase I","graph3":"Gedeon Richter","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Gedeon Richter \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gedeon Richter \/ Inapplicable"},{"orgOrder":0,"company":"Gedeon Richter","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"HUNGARY","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase I","graph3":"Gedeon Richter","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Gedeon Richter \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gedeon Richter \/ Inapplicable"},{"orgOrder":0,"company":"Gedeon Richter","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"ABBV-932","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Gedeon Richter","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Gedeon Richter \/ Gedeon Richter","highestDevelopmentStatusID":"8","companyTruncated":"Gedeon Richter \/ Gedeon Richter"},{"orgOrder":0,"company":"Gedeon Richter","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2020","type":"Acquisition","leadProduct":"Norelgestromin","moa":"||Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Gedeon Richter","amount2":0.26000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.26000000000000001,"dosageForm":"Patch","sponsorNew":"Gedeon Richter \/ Gedeon Richter","highestDevelopmentStatusID":"15","companyTruncated":"Gedeon Richter \/ Gedeon Richter"},{"orgOrder":0,"company":"Gedeon Richter","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"HUNGARY","productType":"Antibody","year":"2021","type":"Licensing Agreement","leadProduct":"Denosumab","moa":"Tumor necrosis factor ligand superfamily member 11","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Gedeon Richter","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gedeon Richter \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Gedeon Richter \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"Gedeon Richter","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"HUNGARY","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"RGB-14-P","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Gedeon Richter","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gedeon Richter \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Gedeon Richter \/ Inapplicable"},{"orgOrder":0,"company":"Gedeon Richter","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"HUNGARY","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Gedeon Richter","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gedeon Richter \/ AbbVie Inc","highestDevelopmentStatusID":"4","companyTruncated":"Gedeon Richter \/ AbbVie Inc"},{"orgOrder":0,"company":"Gedeon Richter","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"HUNGARY","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Gedeon Richter","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gedeon Richter \/ AbbVie Inc","highestDevelopmentStatusID":"3","companyTruncated":"Gedeon Richter \/ AbbVie Inc"},{"orgOrder":0,"company":"Gedeon Richter","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"HUNGARY","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Azilsartan","moa":"Type-1 angiotensin II receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Gedeon Richter","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gedeon Richter \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Gedeon Richter \/ Undisclosed"},{"orgOrder":0,"company":"Gedeon Richter","sponsor":"Bio-Thera Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Gedeon Richter","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gedeon Richter \/ Gedeon Richter","highestDevelopmentStatusID":"15","companyTruncated":"Gedeon Richter \/ Gedeon Richter"}]

    Find Clinical Drug Pipeline Developments & Deals by Gedeon Richter

    Menu

    Gedeon Richter

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    EXCIPIENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Gedeon Richter

                            Hungary arrow
                            World Drug Safety EU
                            Not Confirmed

                            Gedeon Richter

                            Hungary arrow
                            World Drug Safety EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ustekinumab

                            Therapeutic Area : Immunology

                            Study Phase : Approved FDF

                            Recipient : Bio-Thera Solutions

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            EC Approves Bio-Thera’s Stelara Biosimilar USYMRO

                            Details : Usymro (ustekinumab) is a human IL-12 and IL-23 antagonist indicated for the treatment of adult patients with moderate to severe Crohn’s disease.

                            Product Name : Usymro

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            August 26, 2025

                            Lead Product(s) : Ustekinumab

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved FDF

                            Recipient : Bio-Thera Solutions

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Gedeon Richter

                            Hungary arrow
                            World Drug Safety EU
                            Not Confirmed

                            Gedeon Richter

                            Hungary arrow
                            World Drug Safety EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Azilsartan

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Azilsartan 80mg Vs Edarbi 80mg Bioequivalence Study

                            Details : Azilsartan is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Hypertension.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 25, 2025

                            Lead Product(s) : Azilsartan

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Gedeon Richter

                            Hungary arrow
                            World Drug Safety EU
                            Not Confirmed

                            Gedeon Richter

                            Hungary arrow
                            World Drug Safety EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Empagliflozin

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pharmacokinetics and Bioequivalence Study of Empagliflozin+Metformin Hydrochloride 12.5 mg/1000 mg Film-coated...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            February 12, 2025

                            Lead Product(s) : Empagliflozin

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Gedeon Richter

                            Hungary arrow
                            World Drug Safety EU
                            Not Confirmed

                            Gedeon Richter

                            Hungary arrow
                            World Drug Safety EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Empagliflozin

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pharmacokinetics and Bioequivalence Study of Empagliflozin+Metformin Hydrochloride 5 mg/1000 mg Film-coated Ta...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 27, 2025

                            Lead Product(s) : Empagliflozin

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Gedeon Richter

                            Hungary arrow
                            World Drug Safety EU
                            Not Confirmed

                            Gedeon Richter

                            Hungary arrow
                            World Drug Safety EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Empagliflozin

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pharmacokinetics and Bioequivalence Study of Empagliflozin+Metformin Hydrochloride 5 mg/850 mg Film-coated Tab...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 09, 2025

                            Lead Product(s) : Empagliflozin

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Gedeon Richter

                            Hungary arrow
                            World Drug Safety EU
                            Not Confirmed

                            Gedeon Richter

                            Hungary arrow
                            World Drug Safety EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Discovery Platform

                            Sponsor : AbbVie Inc

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            AbbVie, Gedeon Richter Partner on Neuropsychiatric Drug Discovery

                            Details : Companies will discover and develop novel targets for the treatment of neuropsychiatric conditions. AbbVie will have worldwide commercialization rights except for traditional markets of Richter.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : $25.0 million

                            October 24, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Discovery Platform

                            Sponsor : AbbVie Inc

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Gedeon Richter

                            Hungary arrow
                            World Drug Safety EU
                            Not Confirmed

                            Gedeon Richter

                            Hungary arrow
                            World Drug Safety EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Relugolix,Estradiol,Norethisterone Acetate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase III

                            Sponsor : Sumitomo

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Gedeon Richter and Sumitomo Pharma Receive Positive CHMP Opinion for RYEQO® for Treatment of Endometriosis

                            Details : Ryeqo (relugolix, estradiol, and norethisterone acetate) receives positive opinion by CHMP recommending approval in for the adjuvant treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis.

                            Product Name : Ryeqo

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 15, 2023

                            Lead Product(s) : Relugolix,Estradiol,Norethisterone Acetate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase III

                            Sponsor : Sumitomo

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Gedeon Richter

                            Hungary arrow
                            World Drug Safety EU
                            Not Confirmed

                            Gedeon Richter

                            Hungary arrow
                            World Drug Safety EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ABBV-932

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Recipient : AbbVie Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Assess Adverse Events and How ABBV-932 Oral Capsules Moves Through the Body of Healthy Adult Particip...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            February 22, 2023

                            Lead Product(s) : ABBV-932

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Recipient : AbbVie Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Gedeon Richter

                            Hungary arrow
                            World Drug Safety EU
                            Not Confirmed

                            Gedeon Richter

                            Hungary arrow
                            World Drug Safety EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Relugolix,Estradiol,Norethisterone Acetate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            European Commission Approves the Commercialisation of RYEQO® for the Symptomatic Treatment of Endometriosis

                            Details : Ryeqo (relugolix, estradiol, and norethisterone acetate) receives approval from EU in for the adjuvant treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis.

                            Product Name : Ryeqo

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            February 11, 2023

                            Lead Product(s) : Relugolix,Estradiol,Norethisterone Acetate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Gedeon Richter

                            Hungary arrow
                            World Drug Safety EU
                            Not Confirmed

                            Gedeon Richter

                            Hungary arrow
                            World Drug Safety EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Preclinical

                            Sponsor : AbbVie Inc

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            AbbVie and Gedeon Richter Announce Collaboration in Neuropsychiatric Diseases

                            Details : The collaboration is based on results of preclinical research carried by Richter and includes several new chemical entities selected for development. AbbVie and Richter have collaborated for 15 years, including globally launched products such as caripraz...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            November 03, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Preclinical

                            Sponsor : AbbVie Inc

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth